BackInnate Pharma Overview

Innate Pharma Other Liabilities

Track Innate Pharma's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Innate Pharma Other Liabilities History

Loading

Innate Pharma vs. peers: Other Liabilities Comparison

Loading

Innate Pharma Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Innate Pharma (IPHA) FAQ

The latest other liabilities for IPHA is $0 as of December 2025. In the prior-year period, the figure was $0. Investors often review this figure alongside Innate Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPHA's other liabilities moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Innate Pharma's operating scale or balance-sheet position.

A other liabilities figure of $0 for IPHA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IPHA's other liabilities ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Innate Pharma's other liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.